Squadron Capital Management
Squadron Capital Management reported 34 stocks worth $292M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are RLMD (17.4%), CCCC (11.5%) and COGT (11.5%). Compared with Q1 2026, the fund opened new positions in ELVN, ADAG and IFRX, added to CCCC, COGT and KOD, trimmed RLMD, EWTX and ANL and sold out of ABVX, NKTR and SCYX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  RLMD Relmada Therapeutics Inc | $50.9M | 17.4% | 7.3M | −1.1M (−13%) | 3 of 3 | |
| 2 |  CCCC C4 Therapeutics Inc | $33.6M | 11.5% | 7.2M | +5M (+220%) | 2 of 3 | |
| 3 |  COGT Cogent Biosciences Inc | $33.5M | 11.5% | 865K | +78K (+10%) | 3 of 3 | |
| 4 |  KOD Kodiak Sciences Inc | $19.5M | 6.7% | 500K | +120K (+32%) | 3 of 3 | |
| 5 |  RLAY Relay Therapeutics Inc | $18.1M | 6.2% | 970K | +298K (+44%) | 2 of 3 | |
| 6 |  ZNTL Zentalis Pharmaceuticals Inc | $17.9M | 6.1% | 3.7M | +69K (+2%) | 2 of 3 | |
| 7 |  EWTX Edgewise Therapeutics Inc | $11.8M | 4.0% | 290K | −60K (−17%) | 3 of 3 | |
| 8 |  MAZE Maze Therapeutics Inc | $10M | 3.4% | 335K | +78K (+30%) | 3 of 3 | |
| 9 |  IVA Inventiva SA | $9.2M | 3.1% | 2.4M | +1.9M (+355%) | 3 of 3 | |
| 10 |  ANL Adlai Nortye Ltd | $8.8M | 3.0% | 765K | −500K (−40%) | 2 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
KALVISTA PHARMACEUTICALS INC | $19.8M | 985K |
 ABVX Abivax SA | $14.5M | 130K |
 NKTR Nektar Therapeutics | $9M | 125K |
 SCYX Scynexis Inc | $7M | 7.6M |
 EPRX Eupraxia Pharmaceuticals Inc | $4.9M | 680K |
🔒 Free account: see all 13.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 AVBP Arrivent Biopharma Inc | Call | $6.4M | 183K | +73,000 |
 BIOA Bioage Labs Inc | Call | $6.1M | 250K | +250,000 |
 RZLT Rezolute Inc | Call | $4.7M | 900K | +900,000 |
 CMPS Compass Pathways PLC | Call | $4.3M | 305K | +305,000 |
 IRON Disc Medicine Inc | Call | $2.2M | 30K | +30,000 |
🔒 Free account: see all 9.
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Squadron Capital Management 13F FAQ
What does Squadron Capital Management own?
Squadron Capital Management reported 34 stocks worth $292M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are RLMD (17.4%), CCCC (11.5%) and COGT (11.5%). The table above lists every position in the filing (the top 10 without an account).
What did Squadron Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 17 new positions, 9 added to, 6 trimmed and 13 sold out. New positions include ELVN, ADAG and IFRX. It sold all of ABVX, NKTR and SCYX.
When will Squadron Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Squadron Capital Management's portfolio worth?
The Q2 2026 filing reports $292M in US stocks ($322M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.